Advertisement
Australia markets close in 1 hour 8 minutes

  • ALL ORDS

    7,846.30
    -163.10 (-2.04%)
     

  • ASX 200

    7,596.30
    -156.20 (-2.02%)
     

  • AUD/USD

    0.6425
    -0.0020 (-0.31%)
     

  • OIL

    85.86
    +0.45 (+0.53%)
     

  • GOLD

    2,401.60
    +18.60 (+0.78%)
     

  • Bitcoin AUD

    97,235.74
    -4,066.20 (-4.01%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • AUD/EUR

    0.6051
    -0.0008 (-0.13%)
     

  • AUD/NZD

    1.0912
    +0.0003 (+0.03%)
     

  • NZX 50

    11,797.67
    -119.11 (-1.00%)
     

  • NASDAQ

    17,706.83
    -296.65 (-1.65%)
     

  • FTSE

    7,965.53
    -30.05 (-0.38%)
     

  • Dow Jones

    37,735.11
    -248.13 (-0.65%)
     

  • DAX

    18,026.58
    +96.26 (+0.54%)
     

  • Hang Seng

    16,279.56
    -320.90 (-1.93%)
     

  • NIKKEI 225

    38,355.69
    -877.11 (-2.24%)
     

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Apellis Pharmaceuticals, Inc.
·1-min read

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET. The conference will be held in a virtual meeting format.

The conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178